May 26, 2019

Cablivi Gets FDA Approval for Rare Blood Clotting Disorder

By Jennifer Barrett, Associate Editor
Published Online: Monday, Feb 11, 2019

Caplacizumab-yhdp was previously granted Priority Review Designation and Orphan Drug Designation. The FDA granted approval to Ablynx, a subsidiary of Sanofi.

References

FDA approves first therapy for the treatment of adult patients with a rare blood clotting disorder [news release]. FDA. https://bit.ly/2UKSPMW. Accessed February 6, 2019.

FDA approves Cablivi (caplacizumab-yhdp), the first Nanobody-based medicine, for adults with acquired thrombotic thrombocytopenic purpura [news release]. Sanofi. https://bit.ly/2HYmAs3. Accessed February 6, 2019.

About the Specialty Pharmacy Times Industry Guide

The Specialty Pharmacy Times Industry Guide includes comprehensive editorial content relative to all specialty pharmacy stakeholders. Content includes information relative to market trends, commercialization, distribution, order to cash, HUB Services, managed care strategies and DIR fees. The guide also includes profiles, and a complete list of stakeholders along the patient journey: specialty pharmacies, wholesaler distributors, manufacturers, support services, group purchasing, and trade associations.

Sign Up for the Industry Guide Newsletter

Copyright © 2006-2018 Pharmacy & Healthcare Communications, LLC
All Rights Reserved

About Us